Tesla’s ‘Model Q’ to arrive in 2025 at a price under $30K, Deutsche Bank says Ivar AI

Ambcrypto.com

Crypto market cap surpasses France, UK GDPs – India, Japan next

GlobeNewswire

The Rise of Social Media Management Market: A $ 51.8 billion Industry Dominated by IBM (US) and Cisco (US) | MarketsandMarkets™

Biztoc.com

Alphabet stock adds $136 billion in market value after it unveils quantum computing breakthrough

Biztoc.com

Buy Palantir Stock Before It Soars 200% to $500 Billion, According to a Wall Street Analyst

The Daily Hodl

Treasury Department’s FSOC Says Stablecoins Represent Potential Risk to US Financial Stability

TechRadar

Amazon teams up with Samsung rival to design and build bespoke next generation tech that will help AWS pull ahead in the hyperscaler race

The Daily Hodl

Trader Turns $3,000 Investment Into $73,000,000 With Frog-Themed Memecoin PEPE: Lookonchain

Biztoc.com

Alexis Ohanian Says This Is His Best Investment So Far: $10,000 Turned Into More Than $17 Million

ABC News

Five years since its inception, a US development agency competes with China on global projects

CryptoSlate

Bitcoin poised for ‘golden age’ in 2025 with $200k milestone projection – Bitwise

Biztoc.com

Bill Gates: How Entrepreneurs Can Benefit From Climate Change

Biztoc.com

Mark Zuckerberg's Soaring Wealth: Billionaire Now Richer Than Warren Buffett, Mark Cuban, Peter Thiel And Ken Griffin Combined

$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

GlobeNewswire

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

International Business Times

Taiwan Says China Carrying Out Huge Maritime Drills

$Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients$

GlobeNewswire

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients